| Literature DB >> 35707965 |
Subarna Barua1, Chad H Newbolt2, Stephen S Ditchkoff2, Calvin Johnson1, Sarah Zohdy2, Rachel Smith1, Chengming Wang1.
Abstract
Entities:
Mesh:
Year: 2022 PMID: 35707965 PMCID: PMC9246038 DOI: 10.1080/22221751.2022.2090282
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 19.568
Molecular and serological prevalence of SARS-CoV-2 in deer
| Country, State | Sampling period | Sample; detection method | Prevalence; SARS-CoV-2 lineages identified | Reference |
|---|---|---|---|---|
| USA: OH | January–March, 2021 | Nasal swabs; RT-PCR | 35.8%; 129/360; B.1.2, B.1.596, B.1.582 | [ |
| USA: MI, PA, IL, NY | 2011–2021 | Serum; sVNT | 40.0%; 152/624 | [ |
| USA: IA | April 2020–January 2021 | Retropharyngeal lymph node; RT-PCR | 33.2%; 94/283; B.1, B.1.1, B.1.119, B.1.2 51, B.1.234, B.1.240, B.1.264, B.1.311, B.1.362, B.1.400, B.1.459, B.1.596 | [ |
| USA: NY | December 2021–January 2022 | Serum; sVNT | 14.5%; 19/131 | [ |
| Nasal swabs; RT-PCR | 10.3%; 7/68 | |||
| USA: TX | January–February 2021 | Serum; plaque reduction neutralization assay | 37.0%; 20/54 | [ |
| USA: TX | September–November 2021 | Serum; plaque reduction neutralization assay | Facility A: 94.4%; 34/36; facility B: 0.0%; 0/16: facility C: 0.0%; 0/29 | [ |
| Respiratory and rectal swabs; RT-PCR | 0.0%; 0/80 | |||
| USA: SC | N/A | Serum; Neutralizing antibody assay | 9.0%; 2/22 | [ |
| Canada: QC | Nov 2021 | Nasal swabs; RPLNs; RT-PCR | 1.2%; 3/251 (nasal swab); 0.0%; 0/104 (RPLNs); B.1.617.2 (lineage AY.44) | [ |
| Thoracic cavity fluid; neutralizing antibody assay | 5.6%; 14/251 | |||
| UK | January 2020–May 2021 | Serum; sVNT | 0.0%; 0/1748 | [ |
| Germany | January 2020–December 2021 | Serum; sVNT | 0.0%; 0/181 | [ |
| Austria | January 2020–December 2021 | Serum; sVNT | 0.0%; 0/51 | [ |